-
Shares of Intellia Therapeutics, Inc.
NTLA
surged 50.2% after the company reported positive clinical data for its CRISPR therapy.
-
Anavex Life Sciences Corp.’s
AVXL
shares jumped 16.6% after the company reported that its ANAVEX2-73 has improved MDS-UPDRS efficacy endpoints with significant biomarker correlation in placebo-controlled Phase 2 clinical trial for treatment of Parkinson’s.
-
Shares of MannKind Corporation
MNKD
rose 11.6% after the company reported that Medicare patients will be able to use its Afrezza and continuous glucose monitoring devices starting in July.
-
Kymera Therapeutics, Inc.’s
KYMR
shares jumped 6.3% after the company reported that its KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report